For investors
A validated science base, a defensible multi-modal platform and a clear EU regulatory path. See why this is a category worth backing.
The investment case →For clinicians & research
Five biomarker streams, each grounded in peer-reviewed literature, validated with named hospital and academic partners.
The science →For care & product
A smartphone session that captures five biomarker streams at once, with a risk score and report for the prescribing specialist.
Our approach →A problem measured in tens of millions of lives.
Neurodegenerative disease is one of the defining health challenges of the century, and the window for acting earliest is exactly the window medicine has been missing.
Sources: WHO; Alzheimer’s Disease International; European Brain Council; Wimo et al., Nature Aging (2024).
Built on evidence, not just ambition.
From a slow, invasive pathway to an early one.
Conventional pathway
- Invasive: blood draws, scans, specialist visits
- Slow: diagnosis arrives once symptoms are clear
- €2,000 to €5,000 per diagnostic episode
- Specialist-bound, one patient at a time
The Deep Medicine objective
- Non-invasive: a session on a standard smartphone
- Early: built to surface risk up to a decade before onset
- Designed to bring a screening episode under €100
- Built for population scale, not single referrals
Latest from Deep Medicine.
What your eyes give away before your memory does.
Eye movements shift measurably in mild cognitive impairment and early Alzheime’s, often before memory complaints. Tracking them needs no clinic, only a camera and the right tasks.
The 170 billion euro problem behind early detection
Neurodegenerative disease already costs Europe 170 billion euro a year, and most of it lands on families. Detection timing is part of that cost.
What the German DiGA pathway means for digital diagnostics
Germany was first to let statutory insurers reimburse certified digital health apps. Here is why that framework shapes our regulatory roadmap.
See the early signal for yourself.
Read the science, or request the confidential investor materials.